JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and a

Bank of America Corp DE lifted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) by 163

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome

Dimensional Fund Advisors LP grew its position in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 19.7% i

Stoke Therapeutics (NASDAQ: STOK) said its Phase III EMPEROR study of zorevunersen in patients with

Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and mainta

Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.

Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and rais

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy a

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks C

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dr

Up to $200,000,000Common StockWe previously entered into a Controlled Equity OfferingSM Sales Agreem

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.93) per share which missed the ana

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a

—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027——Ph

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analy

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy a

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains

Stoke Therapeutics, Inc.Common Stock, Preferred Stock,Debt Securities, Warrants, Subscription Rights

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and rais

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and rais

Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve o

Wolfe Research analyst Rudy Li initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Outp

Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with